Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetics of Digoxin Clear all

Conditions: Heart Failure
Interventions: Digoxin Dosing per Nomogram, Digoxin; Other · Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 22 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease, Huntington Disease
Interventions: digoxin, dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: LY2216684, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: digoxin plus albiglutide; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Heathy Volunteer
Interventions: CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib; Drug · Dietary Supplement
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Digoxin, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neoplasms, Breast
Interventions: lapatinib, Digoxin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Healthy
Interventions: LY3537982, Digoxin, Rosuvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions: Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Single-ventricle, Infant Conditions, Infant, Newborn, Diseases, Infant, Premature, Diseases
Interventions: PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Days to 6 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Durham, North Carolina • Charleston, South Carolina

Conditions: Healthy Volunteers
Interventions: Digoxin, Vandetanib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Midazolam, Digoxin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV Infections
Interventions: CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type2 Diabetes Mellitus
Interventions: Bexagliflozin, Digoxin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Enlicitide, Digoxin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Congenital Heart Disease
Interventions: Digoxin; Drug
Lead sponsor: Christoph P Hornik, MD MPH; Other
Eligibility: Up to 6 Months
Enrollment: 50 participants
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 8 more

Conditions: Healthy Volunteers
Interventions: ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy
Interventions: Pirtobrutinib, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Solid Tumors
Interventions: tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam; Drug · Dietary Supplement
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Fedratinib, Digoxin, Rosuvastatin, Metformin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Digoxin, Dulaglutide; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Volunteers
Interventions: Evacetrapib, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

A Study of LY2216684 and Digoxin in Healthy Subjects

A Drug Interaction Study of Albiglutide and Digoxin

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

PK/PD of Digoxin in Infants With SVHD

Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib

A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

Bexagliflozin Drug/Drug Interaction Study With Digoxin

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

A Study of Evacetrapib and Digoxin in Healthy Participants